Immunogenicity and Safety of a Combination Diphtheria, Tetanus Toxoid, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine Coadministered with a 7- Valent Pneumococcal Conjugate Vaccine and a Haemophilus Influenzae Type b Conjugate Vaccine Michael E. Pichichero, MD, Henry Bernstein, DO, Mark M. Blatter, MD, Lode Schuerman, MD, Brigitte Cheuvart, PhD, Sandra J. Holmes, PhD, MHA The Journal of Pediatrics Volume 151, Issue 1, Pages 43-49.e2 (July 2007) DOI: 10.1016/j.jpeds.2007.02.013 Copyright © 2007 Mosby, Inc. Terms and Conditions
Figure Study design. *For the separate administration group, HepB was not to be administered at 4 months of age to subjects who received a dose of hepatitis B vaccine before enrollment in this study. DTaP indicates diphtheria–tetanus–acellular pertussis vaccine; HepB, hepatitis B vaccine; Hib, H influenzae type b vaccine; IPV, inactivated poliovirus vaccine; mos, months; PCV-7, pneumococcal conjugate vaccine; wks = weeks. The Journal of Pediatrics 2007 151, 43-49.e2DOI: (10.1016/j.jpeds.2007.02.013) Copyright © 2007 Mosby, Inc. Terms and Conditions